ArticleBMC cancer2023

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.

Jiao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.